Web1 jul. 2004 · Drug-drug interactions are the same as those occurring with the unmodified IFN product. Conclusions: The pharmacokinetic profile of IFN alfa-2a is improved by pegylation, which enables less frequent administration and results in improved efficacy with a similar side-effect profile. WebMethods: The patients were given antiviral therapy with IFN-α-2b, 3 million units 3 times a week and 800-1,200 mg of ribavirin daily adjusted to the patient's body weight (<60 kg 800 mg day−1, and >60 kg 1,200 day−1).
HIGHLIGHTS OF PRESCRIBING INFORMATION
Web23 nov. 2010 · Conjugation of IFN alpha-2 to PEG determines an evident loss of its in vitro activity. The antiviral activity of the branched 40-kDa PEG-IFN is only 7% of the linear 12 … Web1 jan. 2014 · Pegylated interferon, a biologically engineered interferon aimed to improve its pharmacokinetics and pharmacodynamic properties (increased half‐life), has been studied in a large cohort of patients with melanoma. ... Adjuvant therapy with pegylated interferon alfa‐2b versus observation alone in resected stage III melanoma: ... marine renewables conference
Pharmacokinetics of an extended-release human interferon alpha …
WebRO 25-8310/000; RO-25-8310/000; RO-258310000; Pharmacology Indication. Peginterferon alfa-2a is indicated for the treatment of HCV in combination with other antiviral drugs in … Web28 dec. 2012 · The synergistic combination of interferon (IFN) alpha-2b and IFN gamma results in more potent in vitro biological effects mediated by both IFNs. The aim of this … Web1 mei 2003 · The objective of this study was to compare viral dynamics and pharmacokinetics between peginterferon alpha-2a and peginterferon alpha-2b in … marineofficer_southbay